VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common … Continue reading →

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual … Continue reading →

VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or … Continue reading →

VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment Prevalence of depressive disorders in U.S. … Continue reading →

VTGN is committed to developing and commercializing differentiated new generation medications that go beyond the current standard of care for anxiety, depression and other CNS disorders. VTGN currently has three drugs in its pipeline, PH94B and PH10, both innovative synthetic … Continue reading →

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of … Continue reading →